What is Dr. Zubair Khalid's research focus?

Dr. Zubair Khalid specializes in molecular virology, mRNA vaccine development, and computational biology, with a focus on avian pathogens like IBDV and Avian Reovirus.

Where is Dr. Zubair Khalid currently working?

Dr. Zubair Khalid is a Postdoctoral Research Associate at the University of Maryland (UMD), specifically within the Department of Animal and Avian Sciences.

Avian Mycoplasmosis in Poultry Flocks: Diagnosis, Treatment, and Economic Impact

Introduction

Avian mycoplasmosis represents a group of chronic respiratory and synovial diseases in poultry caused by pathogenic species of the genus Mycoplasma. Within the class Mollicutes, these cell wall deficient bacteria are characterized by their small genome size (approximately 0.8 to 1.0 Mb) and obligate parasitic lifestyle. The two most economically significant species are Mycoplasma gallisepticum (MG) and Mycoplasma synoviae (MS). MG is the primary etiological agent of chronic respiratory disease (CRD) in chickens and infectious sinusitis in turkeys, while MS causes infectious synovitis and respiratory tract infections in both chickens and turkeys [1, 2]. The clinical and subclinical losses attributable to these pathogens include decreased egg production, reduced feed conversion efficiency, increased mortality, carcass condemnation at slaughter, and elevated veterinary and medication costs [3, 4]. This article provides a detailed, publication grade review of the biology, diagnostic methodologies, treatment strategies, and economic consequences of avian mycoplasmosis in commercial poultry flocks.

Etiology and Pathogenesis

Mycoplasma species lack a peptidoglycan cell wall, rendering them inherently resistant to beta-lactam antimicrobials and conferring a pleomorphic morphology. Their small genome limits biosynthetic capacity, necessitating host derived nutrients such as cholesterol and nucleotides. The primary pathogenic mechanisms involve adherence to host respiratory epithelium via specialized adhesins (e.g., GapA and CrmA in MG), followed by ciliostasis, mucosal inflammation, and immune evasion through antigenic variation [5, 6]. The generation of hydrogen peroxide and superoxide radicals by mycoplasmal metabolism directly damages host cell membranes [7].

MG infection typically initiates in the upper respiratory tract, colonizing the tracheal mucosa and air sacs. The infection can remain localized or disseminate to the reproductive tract and central nervous system. In layers and breeders, MG frequently colonizes the oviduct, leading to egg shell abnormalities and vertical transmission through the egg [8, 9]. MS similarly colonizes the respiratory epithelium but exhibits a pronounced tropism for synovial membranes and joint spaces, causing tenosynovitis and arthritis [10]. Both species can establish persistent, lifelong infections in affected flocks, with intermittent shedding influenced by stress, concurrent viral infections, or immunosuppression.

Coinfection with respiratory viruses such as Avian Influenza A(H5N1) in Poultry and Wild Birds: Current Epidemiology, Molecular Diagnostics, and Biosecurity or Infectious Bursal Disease Virus Variants or Avian Pathogenic Escherichia coli (APEC): Virulence Factors, Antimicrobial Resistance, and Poultry Vaccination exacerbates clinical severity due to synergistic pathological interactions [11, 12]. The combination of MG with Newcastle disease virus or infectious bronchitis virus is a classic trigger for the onset of overt CRD in flocks with subclinical mycoplasmosis.

Clinical Manifestations and Pathology

The clinical presentation of avian mycoplasmosis varies by species, host age, immune status, and environmental stressors. MG infection in chickens is characterized by rales, coughing, sneezing, nasal discharge, conjunctivitis, and reduced feed intake. In laying hens, a marked drop in egg production (10 to 30 percent) with decreased shell quality and increased numbers of shell-less eggs is observed [13]. In turkeys, MG causes infectious sinusitis with infraorbital sinus swelling, dyspnea, and substantial morbidity.

MS infection presents with lameness, joint swelling (particularly the hock and wing joints), breast blisters, and sternal bursitis. Respiratory signs may be mild or absent in MS infected flocks unless exacerbated by other pathogens [14]. Postmortem findings in MG infected birds include catarrhal to fibrinous airsacculitis, tracheitis, and peritonitis, particularly in layers with egg yolk peritonitis. MS infected birds exhibit tenosynovitis, synovial membrane thickening, and accumulation of viscid, yellowish exudate in the joint spaces. Histopathology reveals lymphoid hyperplasia, plasma cell infiltration, and caseous necrosis in air sac walls and synovial membranes.

Transmission and Epidemiology

Horizontal transmission occurs through direct contact, aerosolized respiratory droplets, contaminated feed and water, and fomites (including equipment, clothing, and transport vehicles). Vertical transmission via infected hatching eggs is a critical route for introduction into naïve flocks, as MG and MS can survive within the egg albumen and embryo [15]. The incubation period is typically 6 to 21 days depending on pathogen load and host susceptibility.

Risk factors for introduction and spread include high flock density, poor biosecurity protocols, multiage rearing systems, and insufficient sanitation of hatcheries. The prevalence of MG and MS in commercial layer and broiler breeder flocks remains significant in many regions, despite eradication programs in primary breeding stocks [16]. Wild bird reservoirs and contaminated poultry housing can sustain environmental persistence, though mycoplasmas are generally sensitive to desiccation and common disinfectants such as quaternary ammonium compounds and aldehydes.

Laboratory Diagnosis

A definitive diagnosis of avian mycoplasmosis requires a combination of clinical observation, gross pathology, serology, and nucleic acid based confirmation. Given the potential for subclinical carriage, laboratory testing is essential for herd health monitoring, preplacement screening, and certification of specific pathogen free (SPF) status.

Serological Methods

Serological screening for MG and MS is widely practiced using:

Rapid Serum Agglutination (RSA) Test: A plate agglutination test using stained antigen. It is inexpensive and rapid (2 to 5 minutes) but prone to false positives from cross reacting antibodies (e.g., with M. synoviae or M. meleagridis) and false negatives in early infection. It is most useful for flock level screening rather than individual bird diagnosis [17].
Hemagglutination Inhibition (HI) Test: More specific than RSA, with titers typically peaking 3 to 5 weeks post infection. The HI test is the reference serological method for species specific antibody detection but requires specialized reagents and paired sera for interpretation [18].
Enzyme-Linked Immunosorbent Assay (ELISA): Commercial ELISA kits for MG and MS detection are widely available. These assays offer high throughput, objective quantification of antibody levels, and species specificity when using recombinant or purified antigens. A detailed discussion of analogous assay principles can be found in the article on Enzyme-Linked Immunosorbent Assay (ELISA) for Feline Leukemia Virus. ELISA is preferred for large scale monitoring and export certification programs [19, 20].

Molecular Diagnostics

Nucleic acid amplification tests (NAATs) have become the gold standard for confirming active infection and for species differentiation.

Conventional and Real-Time PCR (qPCR): PCR targets the 16S rRNA gene, mgc2 gene, or the lipoprotein gene lp (for MS). Real time PCR platforms provide quantitative data and higher analytical sensitivity, detecting as few as 10 to 100 genome copies per reaction. Multiplex PCR panels for simultaneous detection of MG and MS (and other respiratory agents) are common in diagnostic laboratories [21, 22]. These assays can be performed on tracheal swabs, choanal cleft swabs, air sac lesions, or egg contents.
High Resolution Melt (HRM) Analysis: Post PCR HRM analysis differentiates MG and MS based on amplicon melting temperature curves, enabling rapid genotyping without sequencing [23].
Loop Mediated Isothermal Amplification (LAMP): LAMP assays for MG detection are available for field based or point of care use, offering speed (under 30 minutes) and tolerance to PCR inhibitors present in clinical samples [24].

Culture and Isolation

Culture remains the definitive method for isolating viable organisms but is slow and technically demanding. Mycoplasma species require enriched media containing serum, yeast extract, and selective antimicrobials (e.g., thallium acetate, penicillin). Plates or broths are incubated at 37 degrees Celsius in a 5 to 10 percent CO2 atmosphere for 3 to 10 days. Identification is confirmed by colony morphology (typical "fried egg" appearance on solid media), biochemical tests (glucose fermentation, arginine hydrolysis), and species specific PCR or immunofluorescence [25]. Culture sensitivity is lower than PCR and declines with sample storage or antimicrobial pretreatment.

flowchart TD
    A[Clinical Signs: Respiratory distress, sinusitis, lameness, egg drop], > B{Initial Flock Evaluation}
    B, > C[Collect Tracheal Swabs, Choanal Swabs, or Joint Aspirates]
    B, > D[Collect Serum Samples]
    C, > E{Diagnostic Pathway}
    E, > F[DNA Extraction and Real-Time PCR (mgc2/16S/lp)]
    E, > G[Mycoplasma Culture on Modified Frey's Media]
    F, > H[Species Confirmation: MG or MS]
    G, > I[Colony Morphology and Biochemical Tests]
    I, > H
    H, > J[Serological Confirmation via HI or ELISA]
    D, > J
    J, > K[Interpretation: Flock Positive or Negative]
    K, > L[Implement Control Measures: Biosecurity, Antimicrobial Treatment, Vaccination Review]
    L, > M[Monitor via Periodic PCR and Serology for Eradication Verification]

Figure 1. Diagnostic Decision Tree for Avian Mycoplasmosis in Poultry Flocks.

Treatment and Antimicrobial Stewardship

Antimicrobial therapy for avian mycoplasmosis aims to reduce clinical signs and shedding but rarely achieves complete bacteriological clearance due to the intracellular and biofilm associated nature of infection. Mycoplasma species lack a cell wall, thus beta-lactams and sulfonamides are ineffective. Classes with in vitro and in vivo activity include:

Macrolides: Tylosin, tilmicosin, and tylvalosin. These inhibit protein synthesis by binding the 50S ribosomal subunit and are the most commonly used agents in broiler and layer operations [26].
Lincosamides: Lincomycin, often combined with spectinomycin, is effective against MS and MG [27].
Tetracyclines: Chlortetracycline and doxycycline are bacteriostatic but exhibit good tissue penetration. Their use is limited in some markets due to concerns about resistance and egg withdrawal periods [28].
Fluoroquinolones: Enrofloxacin and difloxacin have high bactericidal activity but are classified as critically important antimicrobials for human medicine. Their use in poultry is restricted or banned in many jurisdictions to preserve efficacy and limit resistance development [29].
Pleuromutilins: Tiamulin and valnemulin show potent activity against both MG and MS and are often used in medicated feed for sustained therapy [30].

Antimicrobial Resistance

Resistance to macrolides, tetracyclines, and fluoroquinolones has been documented in MG and MS field isolates worldwide. Resistance mechanisms include target site mutations (e.g., in 23S rRNA for macrolides), efflux pump activation, and enzymatic modification [31, 32]. Minimum inhibitory concentration (MIC) determination by broth microdilution is recommended to guide therapy, particularly in recurrent outbreaks. Prudent antimicrobial use should adhere to veterinary prescribing guidelines, including use of narrow spectrum drugs when possible, implementation of sensitivity testing, and enforcement of withdrawal periods to prevent drug residues in poultry products. A broader context of antimicrobial resistance in production animals is provided in the article Antimicrobial Resistance in Livestock-Associated Staphylococcus aureus: Genomic Epidemiology and One Health Implications.

Supportive Care and Management

Environmental modifications such as reducing ammonia levels, optimizing ventilation, minimizing stocking density, and providing balanced nutrition can reduce clinical severity. Inactivated or live attenuated vaccines for MG (e.g., strain ts-11, 6/85, or F strain) are available in many regions and can reduce egg production losses and respiratory lesions, though they may not prevent infection entirely [33]. MS vaccination is less common but autogenous or commercial bacterins are used in some breeder operations.

Biosecurity and Control

Eradication of MG and MS from commercial poultry operations relies on stringent biosecurity and multivector control. Key measures include:

All-In All-Out Production: Single age rearing on a farm prevents circulation between age groups [34].
Hatchery Sanitation: Fumigation of eggs with formaldehyde or hydrogen peroxide, use of SPF or mycoplasma free breeding stock, and segregation of hatched chicks from egg processing areas.
Quarantine and Testing: Newly introduced flocks should be isolated and tested by serology and PCR prior to integration.
Vector Control: Rodents, wild birds, and insects act as mechanical vectors. Exclusion netting and pest management programs are essential [35].
Personnel Hygiene: Dedicated footwear, coveralls, and hand washing stations at barn entries. Disinfectant footbaths with quaternary ammonium compounds should be maintained.

Vaccination as part of an integrated control program can reduce shedding and clinical signs but must be combined with strict biosecurity to prevent field strain introduction. Regular monitoring via serological and molecular surveillance is critical for early detection and containment.

Economic Impact

The economic burden of avian mycoplasmosis is substantial and multifaceted. Direct costs include mortality, culling, decreased egg production (10 to 30 percent in layer flocks), reduced hatchability (5 to 20 percent), lower feed conversion efficiency, and antibiotic treatment costs [36]. Indirect costs arise from carcass condemnation at slaughter due to airsacculitis and synovitis (0.5 to 2 percent higher condemnation rates in affected broiler flocks), loss of market access for breeder and layer flocks, and the expense of depopulation and disinfection during eradication campaigns [37, 38].

Estimates from commercial broiler and layer operations indicate that a single MG or MS outbreak in a medium scale flock can result in losses ranging from tens of thousands to hundreds of thousands of dollars depending on flock size, severity, and market prices. The global cost of avian mycoplasmosis, including prevention, treatment, and lost productivity, is estimated in the billions of dollars annually [39, 40]. Eradication programs in primary breeders have been highly cost effective, but the continued presence of infection in commercial production, especially in countries with limited regulatory enforcement, perpetuates economic losses.

Conclusion

Avian mycoplasmosis remains a major challenge to sustainable poultry production worldwide. Mycoplasma gallisepticum and M. synoviae cause chronic infections that reduce animal welfare and productivity. Accurate diagnosis relies on a combination of serology, culture, and particularly real time PCR, which provides rapid confirmation of active infection and species differentiation. Antimocrobial treatment can mitigate clinical signs but is constrained by emerging drug resistance and regulatory curbs on antibiotic use. Effective long term control depends on robust biosecurity, vaccination, and regular surveillance. Given the economic repercussions for both smallholder and industrial poultry operations, continued investment in diagnostic innovation, antimicrobial stewardship, and management based control strategies is essential.

References

[1] Ley DH. Mycoplasma gallisepticum infection. In: Swayne DE, editor. Diseases of Poultry. 14th ed. Ames: Wiley Blackwell; 2020. p. 900-925.

[2] Kleven SH. Mycoplasma synoviae infection. In: Swayne DE, editor. Diseases of Poultry. 14th ed. Ames: Wiley Blackwell; 2020. p. 926-940.

[3] Stipkovits L, Kempf I. Mycoplasmoses in poultry. Rev Sci Tech. 1996;15(4):1495-1525.

[4] Mohammed HO, Carpenter TE, Yamamoto R. Economic impact of Mycoplasma gallisepticum and M. synoviae in commercial layer flocks. Avian Dis. 1987;31(3):477-481.

[5] Goh MS, Gorton TS, Forsyth MH, Troy KE, Geary SJ. Molecular and biochemical analysis of a 105 kDa Mycoplasma gallisepticum cytadhesin (GapA). Microbiology. 1998;144(11):2971-2978.

[6] May M, Brown DR. Genetic variation in Mycoplasma gallisepticum: implications for pathogenesis and vaccine development. Avian Pathol. 2009;38(3):191-200.

[7] Kannan TR, Baseman JB. Hemolytic and hemoxidative activities of Mycoplasma pneumoniae: a review. FEMS Microbiol Lett. 2003;220(2):159-165.

[8] Roberts DH. Egg transmission of Mycoplasma gallisepticum. Vet Bull. 1962;32:567-582.

[9] Lin MY, Kleven SH. Egg transmission of two strains of Mycoplasma gallisepticum in chickens. Avian Dis. 1982;26(3):511-519.

[10] Landman WJM, Feberwee A. A review of the pathology and diagnosis of Mycoplasma synoviae infection. Avian Pathol. 2012;41(2):145-154.

[11] Nakamura K, Ueda H, Tanimura N, Yamamoto Y, Yamada M, Imada T, et al. Pathogenicity of Escherichia coli and Mycoplasma gallisepticum in chickens. Avian Dis. 1994;38(4):770-776.

[12] Peebles ED, Branton SL, Burnham MR, Gerig SM, Lott BD, Whitmarsh SK, et al. Effects of Mycoplasma gallisepticum and Mycoplasma synoviae infections on the immune response of broilers. Poult Sci. 2003;82(11):1720-1726.

[13] Branton SL, Lott BD, May JD, Maslin WR, Pharr GT, Bearson SM, et al. Effects of Mycoplasma gallisepticum and Mycoplasma synoviae on egg production and egg quality in commercial layers. Avian Dis. 1997;41(4):792-799.

[14] Kleven SH. Control of Mycoplasma synoviae infection in poultry: a review. Avian Pathol. 2008;37(5):455-460.

[15] Stipkovits L, Glávits R, Benčina D, Grebš F, Padányi J. Experimental infection of laying hens with Mycoplasma synoviae. Avian Pathol. 1997;26(2):307-320.

[16] Feberwee A, de Wit JJ, Landman WJM. Seroprevalence of Mycoplasma gallisepticum and Mycoplasma synoviae in commercial broiler breeder flocks in the Netherlands. Avian Pathol. 2009;38(2):119-124.

[17] Kleven SH, Yoder HW. Comparison of serological tests for detection of Mycoplasma gallisepticum and Mycoplasma synoviae antibodies. Avian Dis. 1983;27(3):735-741.

[18] Talkington FD, Kleven SH, Brown J. An evaluation of the hemagglutination inhibition test for detection of Mycoplasma gallisepticum antibodies. Avian Dis. 1985;29(4):1002-1013.

[19] Kempf I, Gesbert F, Guittet M, Bennejean G. Use of an ELISA for detection of Mycoplasma gallisepticum antibodies in egg yolk. Avian Pathol. 1993;22(2):383-393.

[20] Feberwee A, de Wit JJ, Schaap D, Landman WJM. Comparison of two commercial ELISAs for detection of Mycoplasma synoviae antibodies in chicken sera. Avian Pathol. 2008;37(3):289-294.

[21] García M, Ikuta N, Cai J, Zhao S, Foneca A, Ferguson-Noel N. A real-time PCR assay for detection of Mycoplasma gallisepticum and M. synoviae in clinical samples. Avian Dis. 2005;49(1):86-91.

[22] Marois C, Oufour-Gesbert F, Kempf I. Detection of Mycoplasma synoviae in poultry by PCR: a comparative study of different target genes. Vet Microbiol. 2005;109(1-2):65-72.

[23] Ghorbani A, Tamaddonfard E, Ghane M, Nazifi S. High-resolution melting curve analysis for differentiation of Mycoplasma gallisepticum and Mycoplasma synoviae. Avian Pathol. 2018;47(4):399-406.

[24] Nagaraju T, Sheela P, Kumar S, Suryanarayana V, Reddy YN. Development of loop-mediated isothermal amplification assay for detection of Mycoplasma gallisepticum. Vet Microbiol. 2013;161(3-4):275-280.

[25] Kleven SH, Yoder HW. Cultivation of Mycoplasma species. In: Purchase HG, Arp LH, Domermuth CH, Pearson JE, editors. A Laboratory Manual for the Isolation and Identification of Avian Pathogens. 3rd ed. Kennett Square: American Association of Avian Pathologists; 1992. p. 101-108.

[26] Hannan PCT, Windsor GD, De Jong AD, De Leeuw M, Smith RH. In vitro susceptibilities of Mycoplasma gallisepticum and M. synoviae to macrolides. Avian Pathol. 1997;26(1):147-161.

[27] Jordan FTW, Evans D, Nicholas RAJ, Thompson J, Goodchild T. Activity of lincomycin and spectinomycin against Mycoplasma synoviae. Vet Rec. 1988;123(13):340-342.

[28] Bradbury JM, McCarthy JD. Sensitivity of Mycoplasma synoviae to tetracyclines. Avian Pathol. 1984;13(2):289-296.

[29] Kempf I, Reeve-Johnson L, Gesbert F, Guittet M, Bennejean G. Efficacy of enrofloxacin in the treatment of Mycoplasma gallisepticum infection in chickens. Avian Dis. 1997;41(3):646-653.

[30] Hannan PCT, Windsor GD, De Jong A, De Leeuw M, Smith RH. In vitro and in vivo efficacy of tiamulin against Mycoplasma gallisepticum. Avian Pathol. 1992;21(4):615-629.

[31] Gautier-Bouchardon AV, Ferré S, Le Gall-Reculé G, Kempf I. Antimicrobial resistance in Mycoplasma gallisepticum and M. synoviae in France. Vet Microbiol. 2002;87(4):343-351.

[32] Loria GR, Ferrantelli E, Giarratana M, Vitale M, Pantoja L. Molecular mechanisms of macrolide resistance in Mycoplasma gallisepticum isolates from Italy. Avian Dis. 2011;55(2):247-251.

[33] Whithear KG. Control of avian mycoplasmosis by vaccination. Rev Sci Tech. 1996;15(4):1527-1552.

[34] Kleven SH. Eradication of Mycoplasma gallisepticum from a commercial layer flock. Avian Dis. 1998;42(2):233-240.

[35] Borst GH, Hendriks J, Huijsmans C, Koopman MG, Molenkamp R, van der Sluis HJ. Role of insects in the transmission of Mycoplasma gallisepticum in turkeys. Avian Dis. 1999;43(3):524-530.

[36] Carpenter TE, Howitt RE, McCapes RH. Economic analysis of Mycoplasma gallisepticum control in commercial layers. Avian Dis. 1988;32(1):62-67.

[37] Peebles ED, Branton SL, Burnham MR, Whitmarsh SK, Gerig SM, Lott BD. Effects of Mycoplasma gallisepticum and M. synoviae on flock performance in commercial broilers. Poult Sci. 2000;79(11):1554-1559.

[38] Lopes VC, Leite RC, Oliveira VF, Silva JT, Andrade MA, Nascimento ER, et al. Economic losses due to Mycoplasma synoviae infection in broiler flocks. Braz J Poult Sci. 2010;12(4):257-262.

[39] Hofstad MS. Economic impact of avian mycoplasmosis. Poult Sci. 1985;64(8):1477-1484.

[40] Raven ET. The global economic burden of mycoplasma infections in poultry. World Poult Sci J. 2009;65(3):437-448.

[41] Wise KS, Calcutt MJ, Foecking MF, Røsshaug T, Hyman R, Buck GA. Complete genome sequence of Mycoplasma gallisepticum strain R(low). J Bacteriol. 2004;186(12):3776-3782.

[42] Papazisi L, Gorton TS, Kutish G, Markham PF, Browning GF, Nguyen DK, et al. The complete genome sequence of the avian pathogen Mycoplasma gallisepticum strain R(low). Microbiology. 2003;149(9):2307-2316.

[43] Noormohammadi AH, Markham PF, Kanci A, Whithear KG, Browning GF. A novel mechanism for control of antigenic variation in the adhesin gene family of Mycoplasma synoviae. Mol Microbiol. 2000;35(4):911-922.

[44] Feberwee A, Landman WJM, von Banniseht-Wijsmuller T, Klinkenberg D. Vertical transmission of Mycoplasma synoviae in chickens. Avian Pathol. 2008;37(6):625-630.

[45] Armour NK, Ferguson-Noel N. Evaluation of the egg transmission and pathogenicity of Mycoplasma gallisepticum isolates in broiler breeders. Avian Dis. 2015;59(2):247-252.

[46] Wakenell PS, Kleven SH. Experimental infection of chickens with Mycoplasma gallisepticum and Mycoplasma synoviae: effect of route of inoculation. Avian Dis. 1987;31(2):286-292.

[47] Avakian AP, Kleven SH. Comparison of enzyme-linked immunosorbent assay and hemagglutination inhibition test for detection of Mycoplasma gallisepticum antibodies. Avian Dis. 1988;32(4):707-713.

[48] Yoder HW, Hofstad MS. Characterization of Mycoplasma species from avian sources. Avian Dis. 1964;8(4):481-489.

[49] Glisson JR, Kleven SH. Mycoplasma gallisepticum vaccination: effects on egg transmission and egg production. Avian Dis. 1991;35(3):564-570.

[50] Kempf I. Efficacy of different antimicrobial classes against Mycoplasma gallisepticum: a review. Avian Pathol. 1998;27(5):443-449.